- Stocks
- Pharma & Healthcare
- Park Medi World
Park Medi World share price
NSE: PARKHOSPSPharma & HealthcareMedical Care Facilities
Park Medi World at a glance
Park Medi World (NSE: PARKHOSPS) closed at ₹220.45 on 22 Oct 2026, down 0.74% on the day. With a market capitalisation of ₹9,522 Cr, it ranks 560th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
At its last close the stock traded at 32.1× trailing earnings, against a return on equity of 12.8% in FY26. Its 52-week range is ₹138.10 (18 Dec 2025) to ₹305.00 (1 Jul 2026); the last close is 27.7% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹476 Cr (+19.4% year on year) and net profit ₹89 Cr (+46.2%), on a consolidated basis. Promoters held 82.89% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹9,522 CrRank 560 on NSE
- P/E (trailing)
- 32.1×
- Price to book
- 4.05×FY26
- EPS (TTM)
- ₹7.22to Q1 FY27
- ROE
- 12.8%FY26
- ROCE
- 18.1%FY26
- Debt to equity
- 0.11FY26
- Net profit margin
- 16.3%FY26
- Book value / share
- ₹46.81FY26
- 52-week high
- ₹305.001 Jul 2026
- 52-week low
- ₹138.1018 Dec 2025
- RSI (14-day)
- 21.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.74% | −8.6% | −22.7% | −21.6% | — |
Park Medi World quarterly results
| Quarter | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹348 Cr | ₹354 Cr | ₹398 Cr | ₹410 Cr | ₹410 Cr | ₹460 Cr | ₹476 Cr |
| Revenue YoY | — | — | — | — | +17.8% | +30.1% | +19.4% |
| Net profit | ₹46 Cr | ₹52 Cr | ₹61 Cr | ₹79 Cr | ₹53 Cr | ₹77 Cr | ₹89 Cr |
| Net profit YoY | — | — | — | — | +15.8% | +46.6% | +46.2% |
| Net margin | 13.1% | 14.8% | 15.2% | 19.1% | 12.9% | 16.7% | 18.6% |
| EPS | ₹1.19 | ₹1.36 | ₹1.58 | ₹2.04 | ₹1.35 | ₹1.78 | ₹2.05 |
Park Medi World financials
| Item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹1,255 Cr | ₹1,231 Cr | ₹1,394 Cr | — |
| Operating profit | ₹317 Cr | ₹221 Cr | ₹287 Cr | — |
| Net profit | ₹228 Cr | ₹152 Cr | ₹213 Cr | — |
| EPS (₹) | ₹6.00 | ₹4.00 | ₹6.00 | — |
| Cash from operations | ₹195 Cr | ₹361 Cr | ₹191 Cr | — |
| Total debt | ₹319 Cr | ₹391 Cr | ₹384 Cr | ₹19 Cr |
| Shareholders' equity | ₹687 Cr | ₹883 Cr | ₹1,070 Cr | ₹2,022 Cr |
Park Medi World shareholding pattern
| Holder | 16 Dec 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|
| Promoters | 82.89% | 82.89% | 82.89% | 82.89% |
| Foreign institutions | 1.97% | 1.28% | 0.86% | 0.82% |
| Domestic institutions | 6.66% | 8.78% | 9.25% | 8.95% |
| Non-institutions | 8.48% | 7.05% | 6.99% | 7.33% |
Park Medi World vs peers
The listed Pharma & Healthcare companies nearest to Park Medi World by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| METROPOLISMetropolis Healthcare | ₹532.25 | −0.03% | +9.2% | ₹11,035 Cr | 57.9 | — |
| AKUMSAkums Drugs and Pharmaceuticals | ₹690.85 | −0.17% | +50.2% | ₹10,874 Cr | 41.5 | — |
| PARKHOSPSPark Medi World | ₹220.45 | −0.74% | — | ₹9,522 Cr | 32.1 | — |
| BLUEJETBlue Jet Healthcare | ₹499.60 | +1.50% | −23.8% | ₹9,456 Cr | 35 | — |
| VIYASHViyash Scientific | ₹214.90 | −0.05% | +3.1% | ₹9,388 Cr | 53.6 | — |
| STARStrides Pharma Science | ₹1,017.30 | −1.23% | +27.8% | ₹9,377 Cr | 16.9 | — |
| YATHARTHYatharth Hospital & Trauma Care Services | ₹932.10 | +1.22% | +14.4% | ₹8,981 Cr | 51.2 | — |
Ask anything about Park Medi World
Pivot answers on the live chart with evidence you can check, and tests strategies against PARKHOSPS's own history. Try: “Why has PARKHOSPS moved over the last three months?” · “Backtest a 50-day moving-average crossover on PARKHOSPS over five years” · “Compare PARKHOSPS with METROPOLIS on margins and valuation”
Frequently asked questions about Park Medi World
What is the share price of Park Medi World today?
Park Medi World (NSE: PARKHOSPS) last closed at ₹220.45 on 22 Oct 2026. Its 52-week high is ₹305.00 and its 52-week low is ₹138.10.
What is the market cap of Park Medi World?
Park Medi World's market capitalisation is ₹9,522 Cr (₹9,522 Cr) at the 22 Oct 2026 close, ranking 560th among the NSE companies Pivot tracks.
What is the P/E ratio of Park Medi World?
Park Medi World trades at a trailing P/E of 32.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 51.2.
What is the ROE and ROCE of Park Medi World?
Return on equity was 12.8% in FY26 and return on capital employed was 18.1% in FY26 (consolidated figures).
Is Park Medi World a debt-free company?
No. Park Medi World's debt-to-equity ratio was 0.11 in FY26, with total debt of ₹19 Cr.
What were Park Medi World's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Park Medi World reported revenue of ₹476 Cr, +19.4% year on year, and net profit of ₹89 Cr, +46.2% year on year.
What is the shareholding pattern of Park Medi World?
As of 30 Jun 2026: promoters 82.89%, foreign institutions 0.82%, domestic institutions 8.95%, non-institutions 7.33%.
Who are Park Medi World's competitors?
The listed Pharma & Healthcare companies closest to Park Medi World by market cap are Metropolis Healthcare, Akums Drugs and Pharmaceuticals, Blue Jet Healthcare, Viyash Scientific, Strides Pharma Science and Yatharth Hospital & Trauma Care Services.
Is Park Medi World a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Park Medi World's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on PARKHOSPS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with P · all NSE stocks · this page as text